Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad5-nCoV Booster After 3 Doses of Inactivated COVID-19 Vaccine
NCT05373030Phase 4Unknown
- Start
- May 2022
- Primary completion
- Dec 2022
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of ad5-ncov in coronavirus disease 2019 (COVID-19) (2 arms). Primary endpoints: Incidence of adverse reactions at 14 days and Geometric mean titer of neutralizing antibody at 14 days. Status: unknown.
02
Drugs
ad5-ncov
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05373030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05373030.